This site is intended for healthcare professionals
Drug News

VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate

Read time: 1 mins
Last updated:2nd Jun 2020
Published:2nd Jun 2020
Condition: Ovarian Cancer
Type: drug
Register free for full access to